Gautam Borthakur

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Lenalidomide as a novel treatment of acute myeloid leukemia
    Yiming Chen
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Unit 428, Houston, Texas 77030, USA
    Expert Opin Investig Drugs 22:389-97. 2013
  2. doi request reprint Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia
    Gautam Borthakur
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5819-22. 2012
  3. pmc Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients
    Aref Al-Kali
    Department of Hematology, Mayo Clinic, Rochester, MN, USA
    Haematologica 97:235-40. 2012
  4. doi request reprint Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:3181-5. 2008
  5. doi request reprint Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 115:3217-21. 2009
  6. doi request reprint Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies
    Gautam Borthakur
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:360-6. 2008
  7. pmc Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Gautam Borthakur
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:73-8. 2010
  8. ncbi request reprint Therapy-related acute myelogenous leukemia and myelodysplastic syndrome
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 9:373-7. 2007
  9. pmc Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 49:690-5. 2008
  10. ncbi request reprint Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:800-5. 2007

Detail Information

Publications92

  1. doi request reprint Lenalidomide as a novel treatment of acute myeloid leukemia
    Yiming Chen
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Boulevard, Unit 428, Houston, Texas 77030, USA
    Expert Opin Investig Drugs 22:389-97. 2013
    ..Trials have been conducted for its use in higher-risk MDS and acute myeloid leukemia (AML)...
  2. doi request reprint Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia
    Gautam Borthakur
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5819-22. 2012
    ....
  3. pmc Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients
    Aref Al-Kali
    Department of Hematology, Mayo Clinic, Rochester, MN, USA
    Haematologica 97:235-40. 2012
    ..It is unclear in the literature whether the outcome of hypocellular acute myeloid leukemia differs from that of non-hypocellular acute myeloid leukemia...
  4. doi request reprint Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:3181-5. 2008
    ....
  5. doi request reprint Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 115:3217-21. 2009
    ..Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities...
  6. doi request reprint Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies
    Gautam Borthakur
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:360-6. 2008
    ..A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of XL119 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  7. pmc Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Gautam Borthakur
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:73-8. 2010
    ..Complete remission was achieved in 2 of 6 minimally pre-treated patients. We conclude that the combination of azacitidine and cytarabine is feasible but has limited activity in relapsed/refractory AML...
  8. ncbi request reprint Therapy-related acute myelogenous leukemia and myelodysplastic syndrome
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 9:373-7. 2007
    ..Participation in clinical trials should be encouraged for this patient population because results with available treatment options are clearly suboptimal...
  9. pmc Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 49:690-5. 2008
    ..We conclude that clinically significant responses with decitabine can be seen in patients post-azacitidine failure without significant toxicity...
  10. ncbi request reprint Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:800-5. 2007
    ..Thus, the incidence of IA among CLL patients treated with FCR was comparable with historical rates. The diagnosis of AIHA can be considered even if the DAT is negative. Pre-existing AIHA need not preclude front-line FCR therapy...
  11. doi request reprint Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
    Aziz Nazha
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Am J Hematol 88:961-6. 2013
    ..In multivariate analysis, CIA retained its favorable impact on OS compared to IA. Thus, CIA is an effective and safe therapy for patients ≤60 years with newly diagnosed AML...
  12. doi request reprint Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Carmen Fava
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:5058-63. 2009
    ..These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome...
  13. pmc Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
    Hagop Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1981-7. 2012
    ..Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML...
  14. doi request reprint Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2232-5. 2009
    ..P190(BCR-ABL) CML is rare and is associated with an inferior outcome to therapy with TKI. These patients need to be identified as high-risk patients...
  15. doi request reprint Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 117:1822-7. 2011
    ..This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options...
  16. pmc Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:244-51. 2012
    ..The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies...
  17. doi request reprint Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
    Alfonso Quintas-Cardama
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6315-21. 2009
    ..This risk is discernible as early as 3 months into imatinib therapy by molecular analysis and may provide the rationale to institute therapies that render higher rates of early response...
  18. doi request reprint Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Blood 120:4840-5. 2012
    ..The studies reviewed are registered at www.clinicaltrials.gov as 2009-0172 (NCT00926731) and 2009-0217 (NCT00952588)...
  19. doi request reprint A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 118:722-8. 2012
    ..Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited...
  20. pmc Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
    Lorenzo Falchi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Am J Hematol 88:1024-9. 2013
    ..Deeper MR at 18 or 24 months are not associated with a benefit in TFS or OS. Furthermore, achieving susMR4·5 does not appear to further reduce the risk of transformation or death...
  21. doi request reprint Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy
    Dushyant Verma
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:2673-81. 2010
    ..Clonal evolution is frequently detected in patients developing resistance to imatinib. The outcome of patients with clonal evolution treated with second generation tyrosine kinase inhibitors is not known...
  22. doi request reprint Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Hagop Kantarjian
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 29:3173-8. 2011
    ..Different definitions of progression-free survival (PFS) and event-free survival (EFS) may result in perceived differences in outcomes with tyrosine kinase inhibitor (TKI) therapies in chronic myelogenous leukemia (CML)...
  23. doi request reprint Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:4471-7. 2012
    ..Standard therapy for older patients with acute myeloid leukemia (AML) has a poor outcome. The authors have designed a combination of clofarabine plus low-dose cytarabine followed by a prolonged consolidation alternating with decitabine...
  24. doi request reprint Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77230 1402, USA
    J Clin Oncol 28:2755-60. 2010
    ..Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS)...
  25. doi request reprint Clofarabine combinations as acute myeloid leukemia salvage therapy
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2090-6. 2008
    ..Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine...
  26. doi request reprint A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1638-45. 2008
    ..4 months vs 5.8 months; P = .1). Clofarabine plus low-dose cytarabine has a higher response rate than clofarabine alone with comparable toxicity. This trial is registered at www.clinicaltrials.gov as no. NCT00088218...
  27. doi request reprint Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 114:2037-43. 2009
    ..Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease...
  28. pmc Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
    Gautam Borthakur
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 96:62-8. 2011
    ..A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  29. doi request reprint Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
    Michael S Mathisen
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77005, USA
    Clin Lymphoma Myeloma Leuk 13:139-43. 2013
    ..Other transplant-specific outcomes, including overall survival (OS), were also similar when compared with the control group...
  30. pmc Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
    Farhad Ravandi
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 121:4655-62. 2013
    ..The combination of AZA and sorafenib is effective for patients with relapsed AML and FLT-3-ITD. This trial was registered at clinicaltrials.gov as #NCT01254890...
  31. doi request reprint Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:2912-21. 2009
    ..Dasatinib is a 325-fold more potent inhibitor of Bcr-Abl than imatinib and has been associated with high rates of durable responses in patients with CML in chronic phase (CP) after imatinib failure...
  32. doi request reprint Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
    Koichi Takahashi
    Divison of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030 4009, USA
    Br J Haematol 161:659-66. 2013
    ..Incorporating FLT3i into salvage strategies may improve long-term outcome of patients with AML FLT3-ITD. Prospective studies to validate this conclusion are warranted...
  33. pmc Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 28:1856-62. 2010
    ..Plasma inhibitory assay demonstrated an on-target effect on FLT3 kinase activity. CONCLUSION Sorafenib can be safely combined with chemotherapy, produces a high CR rate in FLT3-mutated patients, and inhibits FLT3 signaling...
  34. doi request reprint Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system
    Wei Gang Tong
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:4462-70. 2012
    ..Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS...
  35. pmc Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:5746-51. 2009
    ..Outcome of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with chromosome 5 and 7 abnormalities (excluding del 5[q]) has been poor, with <10% of patients alive at 2 years...
  36. pmc Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
    Preetesh Jain
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 121:4867-74. 2013
    ..Early responses are predictive for EFS and failure-free survival and to a lesser extent OS, regardless of the treatment modality, although therapies other than standard-dose imatinib result in higher rates of deep early responses...
  37. doi request reprint Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction
    Wei Gang Tong
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3152-9. 2010
    ..Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous leukemia (CML). The safety and efficacy of imatinib in CML patients with pre-existing liver and/or renal dysfunction has not been analyzed...
  38. doi request reprint Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
    Aref Al-Kali
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:327-35. 2011
    ..Current measurement of efficacy for each therapy is judged by its individual impact on overall survival and event-free survival (EFS)...
  39. doi request reprint Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
    Yesid Alvarado
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 115:3709-18. 2009
    ..The European LeukemiaNet recommendations for chronic myeloid leukemia (CML) defined a group of patients with suboptimal response to imatinib. The significance of this response was not well defined...
  40. doi request reprint Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib
    Fabio P S Santos
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:982-91. 2011
    ..Erythropoietic-stimulating agents have been used for treatment of imatinib-induced anemia. There are no data on long-term safety of erythropoietic-stimulating agents in CML patients...
  41. doi request reprint Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes
    Guillermo Garcia-Manero
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:2548-53. 2013
    ..This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens of subcutaneous (SC) decitabine in patients with low- or intermediate-1-risk myelodysplastic syndrome (MDS)...
  42. doi request reprint Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
    Aref Al-Kali
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:365-9. 2013
    ..7%) and overall survival (395 days vs. 500 days, P = 0.057). In summary, RAS mutations are infrequent in patients with MDS and do not appear to negatively impact their outcome...
  43. pmc The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
    Jorge Cortes
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, USA
    Clin Lymphoma Myeloma Leuk 11:421-6. 2011
    ..Patients with less than complete cytogenetic response to second -line therapy or beyond should be considered to have benefit from therapy and the value of this considered in the context of which alternative options are available...
  44. doi request reprint First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:2070-7. 2010
    ..The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph(+) ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793...
  45. doi request reprint Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    Constantine S Tam
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:516-8. 2008
    ..These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies...
  46. ncbi request reprint Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1556-60. 2007
    ..The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented...
  47. doi request reprint Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 9616, USA
    Clin Lymphoma Myeloma Leuk 11:54-9. 2011
    ..Myelosuppression-associated complications were frequent. Pegaspargase was equally effective and easier to administer than L-asparaginase. Augmented hyper-CVAD may be suitable to be studied in younger adults with untreated ALL...
  48. pmc The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 115:5202-9. 2009
    ..To define the prognosis in myelodysplastic syndrome (MDS) and deletion 5q with or without other cytogenetic abnormalities...
  49. doi request reprint Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I
    Nikolai Velev
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3631-7. 2010
    ..The outcome in such patients after stem cell transplantation (SCT) is unknown...
  50. pmc Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
    Aziz Nazha
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 97:1242-5. 2012
    ..We conclude that FLT3-ITD mutations are unstable at follow up and may occur for the first time at relapse. Therefore, FLT3-ITD is not a reliable marker for minimal residual disease in acute myeloid leukemia...
  51. doi request reprint Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome
    Christelle Chacar
    The Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:197-200. 2012
    ..A phase I-II study of bendamustine fractionated twice daily schedule for 4 days identified 75 mg/m(2) intravenously(IV) twice daily for 4 days as a phase II study schedule...
  52. pmc Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS
    Tapan M Kadia
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5550-9. 2012
    ..Activating mutations in RAS are frequently present in patients with acute myeloid leukemia (AML), but their overall prognostic impact is not clear...
  53. doi request reprint Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77025, USA
    J Clin Oncol 30:2204-10. 2012
    ..To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)...
  54. doi request reprint Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
    Alireza Eghtedar
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4614-8. 2012
    ..Ruxolitinib has modest antileukemic activity as a single agent, particularly in patients with post-MPN AML. The study was registered at www.clinicaltrials.gov as NCT00674479...
  55. doi request reprint Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome
    Tapan M Kadia
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 157:312-20. 2012
    ..Infusion reactions occurred in about half the patients and were manageable. Myelosuppression, elevation in liver enzymes, and infections were common. The early mortality in MDS patients was 13% vs. 0% in AA patients...
  56. doi request reprint Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia
    Fabio P S Santos
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:2145-55. 2011
    ..The impact of FMS-like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other than normal karyotype (NK) AML is unclear...
  57. doi request reprint Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas
    Am J Hematol 88:831-7. 2013
    ..In conclusion, ACA occurs in close to one third of patients with IPSS defined lower risk MDS, more common among patients with t-MDS, but has a significant prognostic impact on de novo MDS...
  58. doi request reprint Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase
    Fabio P S Santos
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 11:355-60. 2011
    ..It induces apoptosis of chronic myeloid leukemia (CML) cells in vitro, but the activity of bortezomib in patients with imatinib-resistant CML is unknown...
  59. ncbi request reprint Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
    Gautam Borthakur
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:346-52. 2006
    ..Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models...
  60. doi request reprint A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities
    Yiming Chen
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:341-4. 2012
    ..The overall complete remission rate with or without platelet recovery was 7% (2/27). Activity of lenalidomide was limited to patients with noncomplex cytogenetics...
  61. doi request reprint Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias
    Dan Jones
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Genes Chromosomes Cancer 49:182-91. 2010
    ..Thus, activation of genetic instability, possibly through mitotic spindle dysregulation, leads rapidly to the selection of advantageous single chromosome aneuploidy...
  62. doi request reprint Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia
    Alireza Eghtedar
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 87:317-8. 2012
    ..In conclusion, and consistent with previous reports, the natural history of patients with t(16:16)(p13;q22) is similar to that of classic patients with inv16 AML and therefore should be treated similarly...
  63. doi request reprint Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:3935-43. 2009
    ..The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure...
  64. doi request reprint Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia
    Masamitsu Yanada
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
    Leuk Res 32:1505-9. 2008
    ..38, p=0.02), as was higher platelet count (hazard ratio 1.35, p=0.04). These findings suggest that blood counts at CR, information readily available, are useful in prognostication in AML...
  65. pmc Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    Jorge E Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:398-404. 2010
    ..Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase...
  66. pmc Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
    Alfonso Quintas-Cardama
    UT Anderson Cancer Center, Department of Leukemia, Unit 428 1515 Holcombe Blvd Houston, TX 77030, USA
    Haematologica 96:918-21. 2011
    ..02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation...
  67. doi request reprint Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Ali Al Ameri
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:93-7. 2010
    ..Acute pulmonary failure during remission induction therapy is a serious complication in patients with acute myeloid leukemia (AML). To the authors' knowledge, the course and prognosis of such patients is not well known...
  68. pmc Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia
    Alireza Eghtedar
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma Leuk 13:477-84. 2013
    ..The outcome of patients with CML who discontinue 2G-TKI initial therapy is unknown. We analyzed the characteristics of patients in whom treatment with first-line 2G-TKIs had failed...
  69. pmc Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    Jorge E Cortes
    Departments of Leukemia and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:392-7. 2010
    ..Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant...
  70. ncbi request reprint Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies
    Gautam Borthakur
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2478-83. 2007
    ..However, the profound immunosuppression caused by alemtuzumab has been associated with infectious complications...
  71. pmc XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Apoptosis 16:67-74. 2011
    ..We conclude that at 350 mg/m², AEG35156 is effective in knocking down XIAP in circulating blasts accompanied by the preferential induction of apoptosis in CD34+38- AML stem cells...
  72. doi request reprint Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
    Kiran Naqvi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:4690-3. 2011
    ..These results demonstrate the complexity of the diagnosis of MDS and highlight the need for confirmation of diagnosis when in doubt...
  73. doi request reprint Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia
    Alison Gardner
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:5684-8. 2008
    ..A neutropenic diet is often used to prevent infection in patients with acute myeloid leukemia (AML). Although such a diet potentially entails inconvenience, its value is uncertain...
  74. doi request reprint Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
    Jorge Cortes
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Cancer 118:418-27. 2012
    ..The p53 antisense oligonucleotide cenersen has been shown to sensitize acute myeloid leukemia (AML) stem cells to DNA damaging agents...
  75. doi request reprint Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5418-24. 2009
    ..We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV)...
  76. doi request reprint Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:53-5. 2008
    ..Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease, with many CP patients having an indolent course...
  77. pmc Cause of death in patients with lower-risk myelodysplastic syndrome
    Farshid Dayyani
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:2174-9. 2010
    ..The cause of death (COD) of these patients is not well understood. Identifying the COD could help to guide early therapy decisions...
  78. ncbi request reprint The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    Francis J Giles
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:624-7. 2007
    ..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
  79. ncbi request reprint Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission
    Masamitsu Yanada
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2756-60. 2007
    ..Potential cure of acute myeloid leukemia (AML) is now a widely accepted idea, but it is uncertain whether there is heterogeneity in the failure rate in patients once they have been in complete remission (CR) for various periods of time...
  80. doi request reprint Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
    Sophie Dimicoli
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas
    Am J Hematol 87:127-9. 2012
    ..This data indicates that panobinostat at the dose and schedule studied here has limited activity in lower risk MDS. Am. J. Hematol., 2012. © 2011 Wiley Periodicals, Inc...
  81. doi request reprint Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia
    Gloria N Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5659-66. 2010
    ..Nausea and vomiting in patients with acute myelogenous leukemia (AML) can be from various causes, including the use of high-dose cytarabine...
  82. doi request reprint Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Effrosyni Apostolidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 10:281-4. 2010
    ..Sunitinib is a multitargeted small-molecule inhibitor of the receptor tyrosine kinases involved in cell proliferation and angiogenesis, including vascular endothelial growth factor receptors...
  83. ncbi request reprint Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:713-7. 2007
    ..The specific efficacy in CMML has not been detailed in a large number of patients. The aim of the study was to evaluate the activity and safety of decitabine in CMML...
  84. pmc Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104
    Juliana Benito
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e23108. 2011
    ..Together, these findings strongly suggest that targeting hypoxia in leukemic BM is feasible and may significantly improve leukemia therapy...
  85. doi request reprint Clofarabine: emerging role in leukemias
    Keeran Sampat
    University of Texas, MD Anderson Cancer Center, Leukemia Department, 1515 Holcombe Boulevard, Box 0428, Houston, TX 77030, USA
    Expert Opin Investig Drugs 18:1559-64. 2009
    ..An oral formulation of clofarabine is also currently under development...
  86. ncbi request reprint Imatinib mesylate in the treatment of chronic myelogenous leukemia
    Gautam Borthakur
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Hematol 79:411-9. 2004
    ..The practical aspects of the treatment of CML with imatinib are discussed. The emergence of imatinib resistance, albeit in a small percentage of patients, has prompted an evaluation of innovative treatment strategies...
  87. doi request reprint Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells
    Ismael J Samudio
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 51:911-9. 2010
    ..Our results warrant investigation of MI-63 or its analogs as anti-leukemic agents, alone or in combination with traditional chemotherapeutic agents...
  88. doi request reprint Challenges in surgical management of abdominal pain in the neutropenic cancer patient
    Brian D Badgwell
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1402, USA
    Ann Surg 248:104-9. 2008
    ....
  89. doi request reprint Relapse and death during first remission in acute myeloid leukemia
    Masamitsu Yanada
    Haematologica 93:633-4. 2008
  90. ncbi request reprint Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
    Masamitsu Yanada
    Br J Haematol 138:555-7. 2007
  91. doi request reprint Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia
    Masamitsu Yanada
    Haematologica 93:1263-5. 2008
  92. doi request reprint A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
    Wendy Stock
    Section of Hematology Oncology, University of Chicago Cancer Research Center, 5841 S Maryland, M C 2115, Chicago, IL 60637, USA
    Invest New Drugs 26:331-8. 2008
    ..No correlation was observed between the development of DLT and pharmacokinetics. The RTPD is 1,750 mg. XK469R induced hematological responses in patients with refractory leukemia at tolerable doses...